Haemodynamic effects of a 10-min treatment with a high inspired oxygen concentration in the emergency department: a prospective observational study

Renate Stolmeijer 1, Ellen van Ieperen, Heleen Lameijer, Paul van Beest, Jan Cornelis ter Maaten 2,5, Ewoud ter Avest 5

ABSTRACT

Previous studies show that prolonged exposure to a high inspired oxygen concentration (FiO₂) is associated with unfavourable haemodynamic effects. Until now, it is unknown if similar effects also occur after oxygen therapy of limited duration in the emergency department (ED).

Objectives To investigate the haemodynamic effects of a high FiO₂ administered for a limited duration of time in patients who receive preoxygenation for procedural sedation and analgesia (PSA) in the ED.

Design, settings and participants In a prospective cohort study, cardiac output (CO), stroke volume (SV) and systemic vascular resistance (SVR) were measured using the ClearSight non-invasive CO monitoring system in patients who received preoxygenation for PSA in the ED. Measurements were performed at baseline, after 5 min of preoxygenation via a non-rebreathing mask at 15 L/min and after 5 min of flush rate oxygen administration.

Outcomes measures The primary outcome was defined as the change in CO (L/min) from baseline after subsequent preoxygenation with 15 L/min and flush rate.

Results Sixty patients were included. Mean CO at baseline was 6.5 (6.0–6.9) L/min and decreased to 6.3 (5.8–6.8) L/min after 5 min of oxygen administration at a rate of 15 L/min, and to 6.2 (5.7–6.70) L/min after another 5 min at flush rate (p=0.037). Mean SV remained relatively constant during this period, whereas mean SVR increased markedly (from 781 (649–1067), to 1244 (936–1695) to 1337 (988–1738) dyn/s/cm–5, p<0.001. Sixteen (27%) patients experienced a>10% decrease in CO.

Conclusion Exposure of patients to a high FiO₂ for 5–10 min results in a significant drop in CO in one out of four patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO₂ should be titrated based on deficit whenever this is feasible and high flow oxygen should not be given as a routine treatment.

BACKGROUND

Oxygen is frequently administered in the emergency department (ED) and in the prehospital setting by emergency medical services (EMS). It is used both to treat or prevent hypoxia in acutely ill patients and to preoxygenate (denitrogenate) patients for procedures such as rapid sequence induction (RSI) or procedural sedation and analgesia (PSA). Often, oxygen is administered at a flow of 15 L/min or even higher via a non-rebreathing mask (NRBM) in order to increase the end-expiratory oxygen fraction, and to denitrogenate the lungs, thereby increasing the save apnoea time for PSA or RSI.

Oxygen administration, however, may not be without risk. Previous studies show that prolonged exposure to a high inspired oxygen concentration (FiO₂) is associated with higher mortality rates in patients hospitalised with various conditions. This may be explained by a negative effect on cardiac output (CO), mediated by peripheral and coronary vasoconstriction, resulting from direct effects of oxygen on smooth muscle tone, and by the formation of reactive oxygen species that contribute to (vascular) oxidative stress.

As opposed to hospitalised patients, patients in the prehospital setting and in the
ED normally receive high-flow oxygen only for a limited amount of time. Previous studies show nonetheless that this results in significant hyperoxaemia in many patients. The clinical relevance of this however is largely unknown, as until now the haemodynamic effects of exposure of patients in the ED to a high FiO₂ for only a limited duration of time have never been reported.

Therefore, in the present study, we aim to investigate the haemodynamic effects of a high FiO₂ administered for only a limited duration of time in patients who receive preoxygenation for PSA in the ED.

METHODS
Study setting and design
A single-centre prospective study was performed in a cohort of patients undergoing preoxygenation for PSA in the ED of the Medical Centre Leeuwarden (a teaching hospital in the Netherlands with an 27 000 ED visits yearly) between May 2018 to June 2019 (ClinicalTrials.gov (NCT03930979).

Patient and public involvement
No patients were involved in the design, recruitment or conduct of this study.

Study population
Patients were eligible for inclusion in the study if they were older than 18 years and were about to receive PSA to facilitate a procedure in ED. Patients were excluded if PSA was needed immediately according to the treating physician (no time to obtain informed consent and/or to perform necessary calibration of the system used to measure CO), if they were pregnant, if they presented with significant hypoxia (defined as an oxygen saturation<90% or a pO₂<8.0kPa), if they received oxygen suppletion preinclusion, if they had chronic obstructive pulmonary disease (COPD) GOLD I or II with hypercapnia (pCO₂>6.4kPa) or COPD GOLD III or IV, if they used bleomycine, if they presented with a cardiogenic shock (systolic blood pressure (SBP)<90mm Hg) or if they needed PSA for electrocardioversion or pacing (for reasons of difficulty obtaining a reliable signal to measure CO). Patients could only be included once.

Study protocol
After informed consent was obtained from eligible patients, demographics, medical history and medication use, ECG at presentation and vital signs were obtained. Subsequently, the Clearsight non-invasive CO measurement system was attached to the patient and calibrated for continuous monitoring of blood pressure, CO, SV and SVR. Baseline values for these parameters were established as an average of three repeated measurements. Thereafter, oxygen was administered via a NRBM at a rate of 15L/min from a powered wall source, and measurements (CO, CI, SV and SVR) were repeated after 5min. Thereafter, the rate of oxygen administration was increased to flush rate (30L/min) and after 5min measurements were repeated. No other interventions than oxygen administration were performed during this period, and no medication or intravenous fluids were administered. Thereafter, care as usual was provided for the conduct of PSA. (Figure 1)

Data collection
The following parameters were collected on a dedicated case report form for all included patients: patient demographics including (cardiac) medical history and use of alcohol, nicotine and medication, ECG abnormalities at presentation, ASA classification and indication for PSA, and vital parameters (heart rate (HR), non-invasively measured SBP, oxygen saturation (SpO₂), CO, SV and SVR).

Non-invasive CO measurements
CO was measured non-invasively using The ClearSight system (Edwards Lifesciences). The methodology of the ClearSight is based on Nexfin technology. This consists of pulsatile unloading of the finger arterial walls using an inflatable finger cuff with a built-in photoelectric plethysmograph that uses pressure to maintain a constant blood volume in the finger. ClearSight calculates beat-to-beat SV by dividing the area under the SBP curve (measured at 200Hz) by the aortic input impedance (Zin). The value of Zin is determined from a three-element Windkessel model in which the nonlinear effect of MAP and the influence of the patient’s age, height, weight and gender on aortic mechanical properties are incorporated. Because the waveform at the finger shows a more undulatory appearance than the radial pressure waveform, the system transforms the finger waveform into a brachial waveform with a specific filter. ClearSight uses the integrated area under the pulsatile systolic waveform from the brachial pressure wave as an input to the model, which directly yields SV and produces CO by multiplying beat-to-beat SV by instantaneous HR. The Nexfin technology used in the ClearSight is validated in multiple studies. Measurements can reliably be performed in awake patients or during cardiac arrhythmias, but hypoperfusion of the finger (due to vasoconstriction) from shock, hypothermia, or the use of vasopressors may negatively impact signal reliability. All investigators received training given by a trainer of the manufacturer of Clearsight in how to operate the device before they were able to include patients for this study.

Figure 1 Study overview. Arrows indicate moments of measurement of haemodynamic parameters.
Outcomes

The primary outcome was defined as the absolute change in CO from baseline after, respectively, 5 min 15 L O₂/min and 5 min flush rate oxygenation via a NRBM.

Secondary outcomes were defined as:
- The absolute change in HR, SBP, SV and SVR from baseline after, respectively, 15 L O₂/min and flush rate oxygenation via NRBM.
- The number of subjects demonstrating a>10% change in CO* in response to oxygen administration (both 15 L/min and Flush rate).
  * a 10% change in CO was deemed clinically relevant as this corresponds to the effect of a Vasalva manoeuvre and has been shown to be a detectable change using a (non-invasive) method based on pulse contour analysis.

Sample size

Based on previous literature, it was estimated that with a mean (SD) CO of 6.0 (0.8) L/min, 54 patients are necessary to allow the detection of a 10% decrease in CO as a result of procedural sedation with a power of 90% and a type I error rate of 5%. To allow for an attrition rate of 10%, we aimed to include 60 patients.

Statistical analysis

Continuous variables are represented as mean (95% CI) or median (IQR) where appropriate. Repeated measures analysis of variance (ANOVA) with Greenhouse Geiser correction and post-hoc testing (Tukey Kramer) was used to analyse the difference in haemodynamic measurements at baseline and after preoxygenation with NRBM 15 L/min and flush rate oxygen. Comparisons between patients demonstrating a>10% decrease in CO and those who did not were made using Student’s t-test, Mann-Whitney U test, or Fisher’s exact test where appropriate. Mixed ANOVA was used to calculate oxygen dose-to-group interactions for these groups. Missing data were reported in the Results section according to the Strengthening the Reporting of Observational Studies in Epidemiology guideline. A p value<0.05 was considered statistically significant. All statistical analysis were done with SPSS V.23.0 for Apple statistical package (SPSS) and Vasarstats statistical software (Vassar College, Poughkeepsie, New York, USA).

RESULTS

Characteristics of study population

During the study period, a total of 91 patients were screened for eligibility. Thirty-one patients were excluded after screening due to various reasons (figure 2). Fourteen patients were excluded as no reliable signal for CO monitoring could be obtained. In 6/14 patients, this was due to identifiable patient factors (cold hands, tremor), whereas in the remaining 8 patients the system software failed.

Baseline characteristics of the study population are shown in table 1. Median (range) age of the included

Table 1 Baseline characteristics of patients preoxygenated with a high (FiO₂) for PSA in the ED (n=60)

| Age in years, median (range) | 62 (18–92) |
|-----------------------------|------------|
| Gender, n (%)               |            |
| Female                      | 30 (50)    |
| Male                        | 30 (50)    |
| Cardiovascular medication use, n (%) |        |
| Beta blocker                | 10 (16,7)  |
| ACE inhibitor or ATII receptor antagonist | 12 (20) |
| Spironolactone              | 1 (1,7)    |
| Calcium channel blockers    | 0 (0)      |
| Known heart failure, n (%)  | 0 (0)      |
| Pacemaker, n (%)            | 0 (0)      |
| Abnormality on ECG, n (%)  | 3 (5)      |

ASA classification, n (%)

| I                           | 21 (35) |
| II                          | 26 (43,3)|
| III                         | 13 (21,7)|
| IV                          | 0 (0)   |
| Use of alcohol<24 hours, n (%) | 17 (29,8) |
| Use of nicotine<24 hours, n (%) | 15 (26,3) |

Indication PSA, n (%)

| Reduction dislocation       | 34 (56,7) |
| Reduction fracture          | 8 (13,3)  |
| Incision and drainage abscess | 17 (28,3) |
| Chest tube placement†       | 1 (1,7)   |

*Atrial fibrillation.
†Indication for the chest tube was a large pneumothorax, without signs of hypoxia, or respiratory or haemodynamic compromise.
ASA, American Society of Anaesthesiologists; ATII, angiotensin type 2; ED, emergency department; PSA, procedural sedation and analgesia.

Stolmeijer R, et al. BMJ Open 2022;12:e059848. doi:10.1136/bmjopen-2021-059848
subjects was 62 (18–92) years, with an equal gender distribution. A total of 16 patients (26.7%) used one or more cardiovascular drugs on a daily basis. There were no patients with pre-existent heart failure or a pacemaker in situ. Other patient characteristics, and vital signs at presentation are represented in table 1. None of the patients received intravenous fluids before arrival in hospital. Sometimes, they did receive analgesics administered by EMS; fentanyl (n=25 (41.7%)), ketamine (n=12 (20%)) or other opioids (n=4 (6.7%)).

Main results

Oxygen administration at a rate of 15 L/min during preoxygenation resulted in an increase in median oxygen saturation (from 97% to 100%), p<0.0001. Mean (95% CI) CO at baseline was 6.5 (6.0–6.9) L/min, and decreased to 6.3 (5.8–6.8) L/min after 5 min of oxygen administration by NRBM at a rate of 15 L/min, and to 6.2 (5.7–6.7) L/min after a further 5 min of flush rate oxygen suppletion (p=0.037). Mean SV remained relatively constant, whereas mean SVR increased markedly (table 2).

A considerable proportion of the subjects (n=16, 27%) demonstrated a>10% decrease in CO in response to preoxygenation: in about a third of the subjects (n=5), this was already apparent after the first 5 min of preoxygenation with an NRBM at a rate of 15 L/min. Baseline patient characteristics were not significantly related to the occurrence of a>10% decrease in CO (table 3).

Patients who demonstrated a>10% decrease in CO had a significantly greater increase in SVR (from 735 dyn/s/cm⁻⁵ at baseline to 1248 dyn/s/cm⁻⁵ after 15 L/min to 1482 dyn/s/cm⁻⁵ after flush rate oxygen suppletion) compared with other patients (846, 1244 and 1304 dyn/s/cm⁻⁵ respectively), p=0.025, figure 3 and table 4. Likewise, they demonstrated a significant decrease in SV (from 86 mL to 76 mL, respectively), whereas SV did not decrease in patient who did not demonstrate a clinically relevant decrease in CO (83, 84 and 86 mL, respectively, p<0.001).

DISCUSSION

In this study, we found that a short 10 min exposure to a high FiO₂ is associated with a significant drop in mean CO. This stresses the importance of titrated oxygen administration in the ED and in prehospital care whenever this is feasible: clinicians should carefully balance the risk of hyperoxia against the risk of hypoxia when oxygen is administered, especially in patients with already compromised circulation.

The observed drop in mean CO in this study is in line with previous literature which shows that prolonged exposure to a high FiO₂ has a negative effect on CO, and (ultimately) on morbidity and mortality. The proposed pathophysiological mechanism mediating the relation between hyperoxia and CO is coronary vasoconstriction, resulting in a decrease in SV. The latter is in line with our finding that SV decreases with>10% in subjects who demonstrated a>10% decrease in their CO, whereas HR remained unchanged. In these patients, we also observed a marked increase in SVR (afterload), which may have contributed to the reduction in CO. Although this may be the result of an increased sympathetic tone due to pain and/or stress, we did not observe a concomitant increase in HR. Alternatively, free oxygen radicals have been shown to modulate the tone of vascular smooth muscle both directly and indirectly by affecting the production or biological activity of vasoactive mediators. Furthermore, free radicals have the potential to damage (mitochondrial) DNA, lipids and proteins, and may cause irreversible damage. However, we can only speculate about the exact aetiology and the relative contribution of the above mentioned processes, as we did not measure free oxygen radicals and/or oxidative stress in our study.

One in four patients demonstrated a>10% drop in CO. Changes of this magnitude are likely clinically relevant in patient who already have a reduced CO, as previous studies have demonstrated that even in healthy volunteers,
a sudden 10% drop in CO (comparable to the effect of a Valsalva manoeuvre) already causes symptoms, whereas a 20% decrease can result in syncope.32 33 Besides, any drop in CO may be undesirable in critically ill patients who are also more prone to develop dysrhythmia’s such as atrial fibrillation, further compromising CO.33 It is worth mentioning, however, that not only the magnitude of the drop in CO, but also the duration are relevant for the ultimate effect. As medication for PSA was administered per protocol after the second period of preoxygenation, we could not monitor (speed of) recovery of CO in our current study, and therefore future studies should focus on reversibility of the observed changes.

As one in four patients demonstrates a>10% drop in CO, it seems reasonable to titrate oxygen administration on SpO2 in patients, especially in patients with an already compromised circulation, even when oxygen is only administered for a short duration of time, as in the prehospital setting or in ED. This can be achieved relatively easy when oxygen is administered for the purpose of treating or preventing hypoxia. But it is more difficult to achieve when oxygen is administered for the purpose

### Table 3  Baseline patient characteristics stratified by the effect of preoxygenation with a high (FiO2) for PSA in the ED (n=60)

| Demographics and history | Patients with a>10% decrease in CO (n=16) | Other patients (n=44) | P value |
|--------------------------|------------------------------------------|----------------------|---------|
| Male (n)                 | 5 (31%)                                  | 25 (57%)             | 0.14    |
| Age (years)              | 67.5 (45.3–77.0)                         | 60 (36.3–74.5)       | 0.45    |
| ASA III classification (n)| 2 (13%)                                  | 11 (25%)             | 0.48    |
| Use of alcohol<24 hours (n)| 5 (31%)                                 | 12 (27%)             | 0.76    |
| Use of nicotine<24 hours (n)| 2 (13%)                               | 13 (30%)             | 0.31    |
| Any cardiovascular medication use (n))| 4 (25%)                                | 12 (27%)             | 1.00    |

### Physical exam

| SpO2 (%)                  | 97 (96–99)                                | 97 (97–98)            | 0.98    |
| HR (beats/min)            | 77 (70–82)                                | 78 (74–82)            | 0.72    |
| SBP                       | 138 (124–160)                             | 133 (123–149)         | 0.63    |
| CO (L/min)                | 6.6 (5.6–7.5)                             | 6.4 (5.9–7.0)         | 0.73    |
| SV (mL)                   | 86 (73–99)                                | 83 (76–90)            | 0.59    |
| SVR (dyn/s/cm−5)          | 735 (637–1142)                            | 846 (649–1042)        | 0.82    |

Values are mean (95% CI) (CO, SV and HR) or median (IQR) (SpO2, SBP, and SVR).

CO, cardiac output; HR, heart rate; SBP, systolic blood pressure; SpO2, oxygen saturation; SV, stroke volume; SVR, systemic vascular resistance.

### Figure 3  Boxplots of stroke volume (SV) and systemic vascular resistance (SVR) as a function of oxygen administration in the emergency department (ED), stratified by response in cardiac output (CO) (>10% decrease or<10% decrease). Represented are median, IQR and ranges (with outliers). Grey boxes represent subjects with a>10% decrease in CO (n=16). White boxes represent subjects with a>10% decrease in CO during the course of the preoxygenation (n=44). Times on the x-axis are baseline, after 5 min and after 10.
of denitrogenation preceding PSA or RSI and thereby increasing save apnoeic time. In those instances, the risk of short duration hyperoxia should be balanced against the risk of the occurrence of hypoxic episodes when preoxygenation with a high FiO₂ is not provided. Although negative effects on CO are undesirable in patients undergoing PSA or RSI (who receive drugs affecting vascular tone and cardiac contractility), the risk of hypoxic episodes probably outweighs this risk in these patients and therefore high FiO₂ should still be given during preoxygenation.

Early use of vasopressors to maintain perfusion pressures in the presence of a reduced CO can be considered under these circumstances.

In other patients, one should ideally aim for a high SpO₂ but at the same time a normal PaO₂ (9.5–13.5 kPa). As continuous blood gas analysis is normally not feasible or appropriate in the prehospital or ED setting, future studies should investigate if there is a role for non-invasive tools to quantify (and prevent) hyperoxia, for example, by estimating the oxygen reserve index.34 35 In the meantime, implementation of checklists, wherein the oxygen requirement and administration are discussed at handover from EMS in ED may increase awareness of the risks associated with hyperoxia and prevent administration of oxygen with a higher than necessary FiO₂.

**Limitations**

Our study has several limitations, inherent to the study design. First, although we observed lower CO and higher SVR values with flush-rate oxygen administration than with 15 L/min, we cannot exclude that this is a time-dependent rather than a dose-dependent effect, as flush rate oxygen was administered immediately after 5 min of oxygen administration by NRBM at a rate of 15 L/min; T=10; value after an additional 5 min of oxygen administration by NRBM at flush rate.

Table 4 Haemodynamic parameters as a function of oxygen administration, stratified by the response in CO (>10% decrease or <10% decrease)

| Parameter | >10% decrease in CO | Other patients | P value |
|-----------|----------------------|----------------|---------|
| CO (L/min) |                       |                |         |
| Baseline  | 6.6 (5.6–7.5)        | 6.4 (5.9–7.0)  | <0.001  |
| Oxygen 15 L/min | 6.2 (5.2–7.2)      | 6.3 (5.7–6.9)  |         |
| Oxygen flush rate | 5.4 (4.6–6.2)     | 6.5 (5.9–7.1)  |         |
| SV (mL)  |                       |                |         |
| Baseline  | 86 (73–99)           | 83 (76–90)     | <0.001  |
| Oxygen 15 L/min | 80 (66–95)       | 84 (76–92)     |         |
| Oxygen flush rate | 76 (61–92)       | 86 (77–94)     |         |
| SVR dyn/s/cm⁵ |                     |                | 0.025   |
| Baseline  | 735 (637–1142)       | 846 (649–1042) |         |
| Oxygen 15 L/min | 1248 (950–1954)  | 1244 (910–1658)|         |
| Oxygen flush rate | 1482 (1129–2214) | 1304 (982–1672)|         |
| HR (beats/min) |                     |                | 0.85    |
| Baseline  | 77 (70–82)           | 78 (74–82)     |         |
| Oxygen 15 L/min | 75 (68–81)       | 77 (72–81)     |         |
| Oxygen flush rate | 75 (68–81)       | 77 (72–82)     |         |
| SBP (mm Hg) |                     |                | 0.26    |
| Baseline  | 138 (124–160)        | 133 (123–150)  |         |
| Oxygen 15 L/min | 147 (117–164)   | 137 (129–164)  |         |
| Oxygen flush rate | 148 (127–165)   | 144 (132–158)  |         |

Values are depicted as mean (95% CI) (CO, SV, HR) or median (IQR) (SBP, SVR). Represented P value are for the oxygen dose-to-group interaction in mixed ANOVA. T=5; value after 5 min of oxygen administration by NRBM at a rate of 15 L/min; T=10; value after an additional 5 min of oxygen administration by NRBM at flush rate.

CO, cardiac output; HR, heart rate; SBP, systolic blood pressure; SV, stroke volume; SVR, systemic vascular resistance.
abuse of nicotine and/or alcohol can lead to cardiovascular impairment, for example, by decreasing coronary blood flow, this could also be a confounding factor.\textsuperscript{37,38} In addition, 25\% of the patients included used cardiovascular medication that could have interacted with the body’s response to a drop in SV and CO from hyperoxia. However, this probably reflects the normal target population in the ED. Finally, generalisability of our results is limited due to the selection of our study population: none of our patients had significant cardiovascular comorbidity. Therefore, no conclusions can be drawn regarding how hyperoxia would affect patients with heart failure, especially when they already have a compromised CO.

CONCLUSION

Exposure of patients to a high FiO\textsubscript{2} for 5–10 min results in a significant drop in CO in one out of four patients. Therefore, even in the ED and in prehospital care, where oxygen is administered for a limited amount of time, FiO\textsubscript{2} should be titrated based on deficit and high flow oxygen should not be given as a routine treatment.

Author affiliations

\textsuperscript{1}Department of Emergency Medicine, University Medical Centre Groningen, Groningen, The Netherlands
\textsuperscript{2}Department of Emergency Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
\textsuperscript{3}Department of Anaesthesiology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands
\textsuperscript{4}Emergency Department, Department of Internal Medicine, University Medical Centre Groningen, Groningen, The Netherlands
\textsuperscript{5}HEMS, Kent, Surrey and Sussex Air Ambulance Trust, Redhill, Surrey, UK

Twitter Ewoud ter Avest @ewoudterAvest

Acknowledgements We want to thank Jack J.M. Litgenberg for his guidance and discussions during this study. We also want to thank all the residents of the Medical Centre Leeuwarden for their help with the inclusion of patients.

Contributors RS and EJA conceived the study. Evi, RS and EJA acquired and interpreted the data. RS and EJA drafted the manuscript. NL, P\textsuperscript{2}B and JCA revised the manuscript critically and gave final approval to submission of the manuscript. RS is the guarantor for the overall content.

Funding This work was financially supported by the MCL Research academy (purchase of the finger cuffs). The ClearSight\textsuperscript{\textregistered} system was made available at no cost by Edwards Lifesciences (reference number NL2018.051). Funding institutions had no role in conception, design, or conduct of the study; collection, management, analysis, interpretation, or presentation of the data; or preparation, review, or approval of the manuscript.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by RTPO Leeuwarden (protocol number nWMO 270). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Renate Stolmeijer http://orcid.org/0000-0002-8726-6383
Jan Cornelis ter Maaten http://orcid.org/0000-0002-0353-4011
Ewoud ter Avest http://orcid.org/0000-0002-1462-6130

REFERENCES

1. ACEP. Clinical policy for procedural sedation and analgesia in the emergency department. \textit{Ann Emerg Med} 1998;36:63–77.
2. American Academy of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. \textit{Anesthesiology} 2002;96:1004–17.
3. Thomson D, Cowan T, Loten C, et al. High-flow oxygen in patients undergoing coronary artery bypass grafting: a prospective chart review. \textit{Emerg Med Australas} 2017;29:33–39.
4. Driver BE, Prekker ME, Kornas RL, et al. Flush rate oxygen for emergency airway Preoxygenation. \textit{Ann Emerg Med} 2017;69:1–6.
5. Bourroche G, Bourgain J. Preoxygenation and general anesthesia: a review. \textit{Minerva Anestesiologica} 2015;81:910–20.
6. Damiani E, Adrario E, Girardis M, et al. Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. \textit{Crit Care} 2014;18:711–04-0711-x.
7. Girardis M, Busani S, Damiani E, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU randomized clinical trial. \textit{JAMA} 2016;316:1583–9.
8. de Jonge E, Peelen L, Keijzers PJ, et al. Association between administered oxygen, arterial partial pressure and mortality in mechanically ventilated intensive care unit patients. \textit{Crit Care} 2008;12:R156.
9. Kilgannon JH, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and inhospital mortality. \textit{JAMA} 2010;303:2165–73.
10. Eastwood G, Bellomo R, Bailey M, et al. Arterial oxygen tension and mortality in mechanically ventilated patients. \textit{Intensive Care Med} 2012;38:91–8.
11. Gao Z, Spilk S, Momen A, et al. Vitamin C prevents hyperoxia-mediated coronary vasoconstriction and impairment of myocardial function in healthy subjects. \textit{Eur J Appl Physiol} 2012;112:483–92.
12. Mak S, Egri Z, Tanna G, et al. Vitamin C prevents hyperoxia-mediated vasoconstriction and impairment of endothelium-dependent vasodilation. \textit{Am J Physiol Heart Circ Physiol} 2002;282:H2414–21.
13. Haque WA, Boehmer J, Clemson BS, et al. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. \textit{J Am Coll Cardiol} 1996;27:353–7.
14. Mak S, Azevedo ER, Liu PP, et al. Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure. \textit{Chest} 2001;120:467–73.
15. McNulty PH, King N, Scott S, et al. Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. \textit{Am J Physiol Heart Circ Physiol} 2005;288:H1057–62.
16. Rousseau A, Bak Z, Janer I, et al. Acute hyperoxemia-induced effects on regional blood flow, oxygen consumption and central circulation in man. \textit{Acta Physiol Scand} 2005;183:231–40.
17. Leitch P, Hudson AL, Griggs JE, et al. Incidence of hyperoxia in trauma patients receiving pre-hospital emergency anaesthesia: results of a 5-year retrospective analysis. \textit{Scand J Trauma Resusc Emerg Med} 2021;29:134.
18. Ameloot K, Van De Vijver K, Broch O, et al. Nefixin noninvasive continuous hemodynamic monitoring: validation against continuous pulse contour and intermittent transpulmonary Thermodilution derived cardiac output in critically ill patients. \textit{ScientificWorldJournal} 2013;2013:1–11.
19. Boisson M, Poignard ME, Pontier B, et al. Cardiac output monitoring with Thermodilution pulse-contour analysis vs. non-invasive pulse-contour analysis. \textit{Anesthesiology} 2019;147:735–40.
20. Bogert LWJ, Wesseling KH, Schraa O, et al. Pulse contour cardiac output derived from non-invasive arterial pressure in cardiovascular disease. \textit{Anesthesia} 2018;65:1119–25.
21. Berkelmans GFN, Kuipers S, Westerhof BE, et al. Comparing volume-clamp method and intra-arterial blood pressure measurements in patients with atrial fibrillation admitted to the intensive or medium care unit. \textit{J Clin Monit Comput} 2018;32:439–46.
22 Maggi R, Viscardi V, Furukawa T, et al. Non-invasive continuous blood pressure monitoring of tachycardic episodes during interventional electrophysiology. Europace 2010;12:1616–22.
23 Delaney LJ, Bellomo R, van Haren F. Responsiveness of noninvasive continuous cardiac output monitoring during the Valsalva maneuver. Clin Nurs Res 2020;29:127–32.
24 de Wilde RBP, Schreuder JJ, van den Berg PCM, et al. An evaluation of cardiac output by five arterial pulse contour techniques during cardiac surgery. Anaesthesia 2007;62:760–8.
25 Hall JE. Guyton and Hall textbook of medical physiology. 12th ed. New York: Elsevier, 2011.
26 Stolmeijer R, Bouma HR, Zijlstra JG, et al. A systematic review of the effects of hyperoxia in acutely ill patients: should we aim for less? Biomed Res Int 2018;2018:1–9.
27 Rubanyi GM. Vascular effects of oxygen-derived free radicals. Free Radic Biol Med 1988;4:107–20.
28 Smit B, Smulders YM, Eringa EC, et al. Effects of hyperoxia on vascular tone in animal models: systematic review and meta-analysis. Crit Care 2018;22:189.
29 D’Aquila P, Bellazzi D, Plassard G. Mitochondria in health, aging and diseases: the epigenetic perspective. Biogerontology 2015;16:569–85.
30 Granata S, Dalla Gassa A, Tomei P, et al. Mitochondria: a new therapeutic target in chronic kidney disease. Nutr Metab 2015;12:49.
31 Wang Y, Hekimi S. Mitochondrial dysfunction and longevity in animals: Untangling the knot. Science 2015;350:1204–7.
32 Fu Q, Verheyden B, Wieling W, et al. Cardiac output and sympathetic vasoconstrictor responses during upright tilt to presyncope in healthy humans. J Physiol 2012;590:1839–48.
33 Vincent J-L. Understanding cardiac output. Crit Care 2008;12:174.
34 Scheeren TWL, Belda FJ, Perel A. The oxygen reserve index (ori): a new tool to monitor oxygen therapy. J Clin Monit Comput 2018;32:379–89.
35 Vos JJ, Willems CH, van Amsterdam K, et al. Oxygen reserve index: validation of a new variable. Anesth Analg 2019;129:409–15.
36 Driver BE, Prekker ME, Kornas RL, et al. Flush rate oxygen for emergency airway preoxygenation. Ann Emerg Med 2017;69:1–6.
37 Mukamal KJ. The effects of smoking and drinking on cardiovascular disease and risk factors. Alcohol Res Health 2006;29:199–202.
38 Jalali Z, Khademalhosseini M, Soltani N, et al. Smoking, alcohol and opioids effect on coronary microcirculation: an update overview. BMC Cardiovasc Disord 2021;21:185.